Autres langues Ikena Oncology, Inc.

Actions

IKNA

US45175G1085

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 16/05/2024			Varia. 5j.	Varia. 1 janv.
1,4 ^USD	+4,87 %		+2,19 %	-28,93 %

13/05	Ikena Oncology, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI
12/03	Ikena Oncology, Inc. annonce ses résultats pour l'exercice clos le 31 décembre 2023	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Ikena Oncology Reports First Quarter 2024 Financial Results and Corporate Update	13/05
Ikena Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	13/05
Ikena Oncology : Corporate Presentation - April 2024	16/04
Ikena Oncology to Present at the Stifel 2024 Virtual Targeted Oncology Forum	10/04
Ikena Oncology to Present at the Stifel 2024 Virtual Targeted Oncology Forum	10/04
Ikena Oncology Reports Fourth Quarter and Full Year 2023 Financial Results	12/03
Ikena Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	12/03
North American Morning Briefing : Inflation Data -2-	12/03
Ikena Oncology to Participate in TD Cowen 44th Annual Health Care Conference	27/02
Ikena Oncology Appoints Caroline Germa, M.D. as Chief Medical Officer	21/02
Ikena Oncology, Inc. Announces Executive Changes	21/02
Ikena Oncology to Cut 35% of Workforce to Extend Cash Runway Into H2 2026	18/01
Ikena Oncology Outlines Key Priorities and Provides Corporate Updates	18/01
Ikena Oncology, Inc. Provides Corporate Updates	18/01
Top Premarket Decliners	24/11
Ikena Oncology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11
Ikena Oncology Shares Initial Positive and Differentiated Dose Escalation Data from IK-930 Phase I Trial and Reports Third Quarter 2023 Financial Results	09/11
Ikena Oncology Shares Initial Positive and Differentiated Dose Escalation Data from IK-930 Phase I Trial and Reports Third Quarter 2023 Financial Results	09/11
Ikena Oncology, Inc. Shares Initial Positive and Differentiated Dose Escalation Data from IK-930 Phase I Trial	09/11
Ikena Oncology to Present at Multiple November 2023 Investor Conferences	07/11

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Ikena Oncology, Inc.

Actions

IKNA

US45175G1085

Autres langues

Filtres